Filtered By:
Infectious Disease: Coronavirus
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 385 results found since Jan 2013.
Comprehensive care of adults with respiratory diseases must include vaccines
Vaccines are among the most effective tools we have to improve and save lives, but only if they are administered to eligible patients. In this issue, Naeger et al1 highlight the major opportunities that the health care community has to achieve high adult vaccination rates. These vaccines include those for prevention of coronavirus disease 2019 (COVID-19), pneumococcal, and influenza, diseases that respiratory health professionals are most aware of, plus pertussis (in Tdap), herpes zoster (HZ, shingles), and as of May 3, 2023, respiratory syncytial viral, for which adults with asthma and chronic obstructive pulmonary diseas...
Source: Annals of Allergy, Asthma and Immunology - September 1, 2023 Category: Allergy & Immunology Authors: Barbara P. Yawn, Dennis Williams, Gregory Poland Tags: Editorial Source Type: research
A qualitative investigation into vaccine hesitancy and confidence among people managing allergy
Vaccine hesitancy is multifactorial, and among atopic individuals, is exacerbated by documented, but rare, cases of allergic reactions to coronavirus disease 2019 (COVID-19) vaccines.1 –3 Furthermore, conflicting information regarding the safety of COVID-19 vaccines may have caused confusion among individuals with a history of severe allergies. We performed semistructured qualitative interviews to better understand how some adults and families managing allergy perceive vaccine m essaging and what influences their decisions to be vaccinated.
Source: Annals of Allergy, Asthma and Immunology - August 28, 2023 Category: Allergy & Immunology Authors: Ayel Luis R. Batac, Kaitlyn A. Merrill, Michael A. Golding, Elissa M. Abrams, Philippe B égin, Moshe Ben-Shoshan, Erika Ladouceur, Leslie E. Roos, Vladan Protudjer, Jennifer L.P. Protudjer Tags: Letters Source Type: research
HIV researcher will head NIH ’s infectious disease institute
The infectious disease institute at the U.S. National Institutes of Health (NIH) will soon have its first new chief in nearly 4 decades. Jeanne Marrazzo, an expert on sexually transmitted infections, will become director of the National Institute of Allergy and Infectious Diseases (NIAID) in the fall. She will succeed Anthony Fauci, who
stepped down
in December 2022 after 38 years at NIAID’s helm.
Marrazzo, 61, currently directs the Division of Infectious Diseases at the University of Alabama at Birmingham (UAB). A physician and epidemiologist, she has expertise in HIV prevention, vaginal infections, horm...
Source: ScienceNOW - August 2, 2023 Category: Science Source Type: news
University of Alabama HIV researcher will head NIH ’s infectious disease institute
The infectious disease institute at the U.S. National Institutes of Health (NIH) will soon have its first new chief in nearly 4 decades. Jeanne Marrazzo, an expert on sexually transmitted infections, will become director of the National Institute of Allergy and Infectious Diseases (NIAID) in the fall. She will succeed Anthony Fauci, who
stepped down
in December 2022 after 38 years at NIAID’s helm.
Marrazzo, 61, currently directs the Division of Infectious Diseases at the University of Alabama at Birmingham (UAB). A physician and epidemiologist, she has expertise in HIV prevention, vaginal infections, horm...
Source: ScienceNOW - August 2, 2023 Category: Science Source Type: news
The U.S. Scientist At the Heart of COVID-19 Lab Leak Conspiracies Is Still Trying to Save the World From the Next Pandemic
Ralph Baric stepped onto the auditorium stage at the University of North Carolina, Chapel Hill, and looked out at the sparse audience that had come to hear him speak. On the large projector screen hanging behind him, the following words appeared: How Bad the Next Pandemic Could Be, What Might It Look Like, and Will We be Ready. The date was May 29, 2018.
“Well, I have to admit I’m a little worried about giving this talk,” Baric said. “The reason is being labelled a harbinger of doom.” The screen shifted, and images of the four horsemen of the apocalypse—Death, Famine, War, and Plague&mda...
Source: TIME: Health - July 11, 2023 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 feature freelance Source Type: news
COVID-19, Coronavirus Vaccines, and Possible Association with Lipsch ütz Vulvar Ulcer: A Systematic Review
In conclusion, COVID-19 and immunization against SARS-CoV-2 add to Epstein-Barr virus as plausible triggers of Lipschütz genital ulcer.
Source: Clinical Reviews in Allergy and Immunology - June 26, 2023 Category: Allergy & Immunology Source Type: research
Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients
Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.06.039. Online ahead of print.ABSTRACTBasophil activation test (BAT) can tackle multiple mechanisms underlying acute and delayed hypersensitivity to drugs and vaccines and might complement conventional allergy diagnostics but its role in anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-related hypersensitivity is ill-defined. Therefore, 89 patients with possible hypersensitivity (56 % with delayed mucocutaneous manifestations) to anti-SARS-CoV-2 vaccines were tested with BAT for Macrogol 3350, DMG-PEG 2000, PEG 20000, polysorba...
Source: Vaccine - June 22, 2023 Category: Allergy & Immunology Authors: Patrizia Pignatti Giuseppe Alvise Ramirez Marco Russo Paolo Marraccini Serena Nannipieri Chiara Asperti Fabrizio Della Torre Antonio Tiri Beatrice Maria Gatti Antonella Gurrado Antonio Meriggi Giovanni Benanti Maria Bernadette Cilona Paolo Pigatto Samuele Source Type: research
Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach
This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions.
Source: Journal of Allergy and Clinical Immunology - June 7, 2023 Category: Allergy & Immunology Authors: Matthew Greenhawt, Timothy E. Dribin, Elissa M. Abrams, Marcus Shaker, Derek K. Chu, David B.K. Golden, Cem Akin, Akterini Anagnostou, Faisal ALMuhizi, Waleed Alqurashi, Peter Arkwright, James L. Baldwin, Aleena Banerji, Philippe B égin, Moshe Ben-Shosha Tags: Review article Source Type: research
Companies won ’t share COVID-19 shots, stalling future vaccine research
The U.S. government has tens of millions of unused doses of messenger RNA (mRNA) COVID-19 vaccines, regularly trashing shots as they pass their expiration dates. It’s a dismal reflection on recent vaccine uptake, but it’s also a serious roadblock for scientists testing and developing vaccines that could protect against future variants of SARS-CoV-2—and the next pandemic. Developers need existing vaccines as a benchmark to compare with new candidates. But government contracts with the vaccinemakers, and the companies’ own policies, prohibit the use of the vaccines for research purposes.
“At this stage of the ...
Source: ScienceNOW - May 30, 2023 Category: Science Source Type: news
The COVID-19 virus mutated to outsmart key antibody treatments. Better ones are coming
In 2020, as the COVID-19 pandemic raged and other effective drugs were elusive, monoclonal antibodies (mAbs) emerged as a lifesaving treatment. But now, 3 years later, all the approvals for COVID-19–fighting antibodies have been rescinded in the United States, as mutations of the SARS-CoV-2 virus have left the drugs—which target parts of the original virus—ineffective.
Researchers around the globe are now trying to revive antibody treatments by redesigning them to take aim at targets that are less prone to mutation. “There are new approaches that present a much more challenging task for the virus to evade,” ...
Source: ScienceNOW - May 24, 2023 Category: Science Source Type: news
Evaluation of pediatric patients with suspected polyethylene glycol and polysorbate allergy before mRNA SARS-CoV2 vaccination
This study aimed to retrospectively evaluate the role of polyethylene glycol (PEG) sensitivity in vaccination decision-making in pediatric patients at high risk of allergy or with suspected allergic reactions to the first dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine. Seventeen enrolled patients were found to have decreased readiness to receive the Coronavirus Disease 2019 (COVID-19) vaccine after developing hypersensitivity to multiple and/or injectable drugs. Skin testing was performed. A basophil activation test with PEG-2000 and 4000 was performed on three patients who were ineligible ...
Source: Allergologia et Immunopathologia - May 11, 2023 Category: Allergy & Immunology Authors: Betul Gemici Karaaslan Nihan Burtecene Ulviye Mustu Suheyla Ocak Ozgur Kasapcopur Ayca K ıykım Haluk Cokugras Source Type: research
